Peripheral Arterial Disease | Treatment Algorithms: Claims Data Analysis | US | 2019
Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is closely associated with coronary and cerebrovascular disease. Current treatment practice largely focuses on both lifestyle modifications and the use of statins, antihypertensives, and antiplatelet agents as cornerstone therapies to prevent events such as MI and stroke in these patients. The emergence of PCSK9 inhibitors to achieve aggressive LDL cholesterol lowering on top of statins is another therapeutic option for PAD patients.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAD patients?
- What percentage of PAD patients receive drug therapy within six months of diagnosis, and how quickly do they receive it?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with PAD?
Related Market Assessment Reports
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
